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Abstract
Objectives: To systematically review evidence on depression screening in coronary heart disease (CHD) by assessing the (1)
accuracy of screening tools; (2) effectiveness of treatment; and (3) effect of screening on depression outcomes.
Background: A 2008 American Heart Association (AHA) Science Advisory recommended routine depression screening in
CHD.
Methods: CINAHL, Cochrane, EMBASE, ISI, MEDLINE, PsycINFO and SCOPUS databases searched through December 2, 2011;
manual journal searches; reference lists; citation tracking; trial registries. Included articles (1) compared a depression
screening instrument to a depression diagnosis; (2) compared depression treatment to placebo or usual care in a
randomized controlled trial (RCT); or (3) assessed the effect of screening on depression outcomes in a RCT.
Results: There were few examples of screening tools with good sensitivity and specificity using a priori-defined cutoffs in
more than one patient sample among 15 screening accuracy studies. Depression treatment with antidepressants or
psychotherapy generated modest symptom reductions among post-myocardial infarction (post-MI) and stable CHD
patients (N = 6; effect size = 0.20–0.38), but antidepressants did not improve symptoms more than placebo in 2 heart failure
(HF) trials. Depression treatment did not improve cardiac outcomes. No RCTs investigated the effects of screening on
depression outcomes.
Conclusions: There is evidence that treatment of depression results in modest improvement in depressive symptoms in
post-MI and stable CHD patients, although not in HF patients. There is still no evidence that routine screening for
depression improves depression or cardiac outcomes. The AHA Science Advisory on depression screening should be revised
to reflect this lack of evidence.
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Introduction
Major depressive disorder (MDD) is present in approximately
20% of coronary heart disease (CHD) patients [1] and is
associated with poorer cardiac prognosis [2]. A 2008 American
Heart Association (AHA) Science Advisory recommended routine
depression screening of all CHD patients [3]. Screening is
reasonably considered for important and prevalent conditions
that can be effectively treated, but are not readily detected without
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screening. For screening to be recommended, benefits in excess of
potential harms should be demonstrated in well-conducted
randomized controlled trials (RCTs) [4]. The AHA recommen-
dation, however, was not based on a systematic review of evidence
of likely benefits and harms of the recommended screening
intervention, and a systematic review published one month after
the Science Advisory reported that no trials had tested whether
depression screening in CHD improved patient outcomes [5].
The AHA invests considerable resources in ensuring that
practice guidelines are revised rapidly to reflect new evidence [6].
Providing current evidence-based guidelines also requires that
recommendations not based on sufficient evidence are revised, and
the AHA has done this on a number of occasions [7]. The
objective of the present systematic review was to determine
whether evidence has been accrued in the last 4 years that would
support the AHA Science Advisory on depression screening or
whether the Science Advisory should be revised. Review questions
included:
Key Question #1: What is the accuracy of depression
screening instruments in CHD?
Key Question #2: Does treatment of depression in CHD
improve depressive symptoms or cardiac outcomes?
Key Question #3: Does depression screening in CHD
improve depression outcomes?
Methods
This systematic review updates a previous review from
November 2008 [5]. Detailed methods were registered in the
PROSPERO prospective register of systematic reviews
(CRD42011001670).
Search strategy
To update the previous review [5], we searched the CINAHL,
Cochrane, EMBASE, ISI, MEDLINE, PsycINFO and SCOPUS
databases from January 1, 2008 through December 2, 2011 (File
S1). One search sought studies of screening accuracy (Key
Question #1), and a second sought RCTs of depression treatment
(Key Question #2) and screening (Key Question #3). Additional
searching included reference lists and forward citation of included
articles, relevant systematic reviews (File S2), selected journals
(December 2011–April 2012; File S3), and trial registries.
Identification of eligible studies
Eligible articles were original studies in any language with data
on adult patients in cardiovascular care settings based on diagnosis
or procedure, including mixed populations if CHD data were
reported separately. Eligible diagnostic accuracy studies (Key
Question #1) reported data allowing determination of sensitivity,
specificity, positive predictive value, and negative predictive value
compared to a Diagnostic and Statistical Manual of Mental Disorders
diagnosis of MDD or an International Classification of Diseases
depressive episode, established with a validated diagnostic
interview administered within 2 weeks of the screening tool.
Eligible articles for Key Question #2 were RCTs comparing
depression treatment with placebo or usual care among CHD
patients with MDD or an International Classification of Diseases
depressive episode based on a validated diagnostic interview. For
trials of patients with MDD and other conditions (e.g., minor
depression), we sought original study data for patients with MDD
for trials with 80% power to detect a 0.50 standardized mean
difference effect size (n = 64 per group). Eligible articles for Key
Question #3 were RCTs that compared depression outcomes
between CHD patients who underwent depression screening and
those who did not.
Two investigators independently reviewed titles/abstracts for
eligibility with full-text review of articles identified as potentially
eligible by one or both. Disagreements after full-text review were
resolved by consensus. Chance-corrected agreement was assessed
with Cohen’s k.
Evaluation of eligible studies
Two investigators independently extracted study data (File S4)
and assessed risk of bias with discrepancies resolved by consensus.
Risk of bias was assessed with the revised Quality Assessment for
Diagnostic Accuracy Studies tool for Key Question #1 (File S5)
and the Cochrane Risk of Bias tool for Key Question #2 (File S6).
Data presentation and synthesis
For Key Question #1 (diagnostic accuracy), data were
extracted based on optimal cutoffs identified by study authors.
For Key Question #2 (treatment) when multiple outcomes were
reported, designated primary outcomes were prioritized, followed
by observer-rated scales, then self-report measures. Post-interven-
tion effect sizes were reported using the Hedges’s g statistic
(standardized difference between 2 means). The most compre-
hensive cardiovascular outcome available was extracted.
For Key Question #1, studies were heterogeneous in terms of
patient samples, screening tools and cutoffs, and whether they used
standard scoring thresholds versus sample-specific thresholds
based on exploratory data analysis. For Key Question #2, studies
had heterogeneous patient samples, therapeutic interventions, and
treatment durations. No eligible studies were identified for Key
Question #3. Thus, results were not pooled quantitatively.
Results
Key Question #1: Diagnostic Accuracy
Of 1,442 citations, 1,405 were excluded after title/abstract
review and 29 after full-text review, leaving 8 eligible articles
(Figure 1; k=1) [8–15], although one [9] was included in the
previous review. Two additional articles were identified through
other methods [16,17]. Adding these to 9 from the previous review
[9,18–25] resulted in 18 articles [8–25] on 15 unique cohorts
(Table 1). Two studies [26,27] from the previous review were
excluded because they did not meet the revised eligibility criterion
of #2 weeks between screening tool and diagnostic interview
administration for all patients.
Sample sizes in the 15 cohorts ranged from 40 to 1,024
(median= 209) and MDD cases from 6 to 224 (median= 35).
Diagnostic accuracy was based on a standard cutoff score for 6
cohorts [8,9,13,16,19,20], on exploratory methods for 7
[12,14,15,17,18,23–25], not specified in 1 [21], and on both
exploratory methods and standard cutoffs in different articles for 1
cohort [10,11,22].
Two studies tested the standard cutoff of $10 on the Beck
Depression Inventory. One reported good sensitivity (82%) and
specificity (78%) post-myocardial infarction (post-MI) [19],
whereas the other reported good sensitivity (88%) but poor
specificity (58%) with hospitalized heart failure (HF) patients [20].
For the Beck Depression Inventory-II, two studies [9,17] reported
good sensitivity (89–91%), but lower specificity (74–78%) based on
the standard cutoff of $14. In one cohort [11,22], the Patient
Health Questionnaire (PHQ-9) had poor sensitivity (54%), but
good specificity (90%) with a standard cutoff of $10, and a cutoff
score of $6 maximized sensitivity (83%) and specificity (76%),
consistent with results from another cohort [25].
Depression Screening in Cardiovascular Care
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Risk of bias was unclear or high for 10 of 18 articles that did not
pre-specify a cutoff for the screening test. With one exception [17],
no studies excluded already diagnosed or treated patients who
would not be screened to identify new cases in clinical settings (File
S7).
Figure 1. PRISMA Flow Diagram of Study Selection Process for Key Question #1.
doi:10.1371/journal.pone.0052654.g001
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Key Question #2: Treatment
Of 1,453 unique titles/abstracts, 1,437 were excluded after
title/abstract review and 14 after full-text review, leaving 2 eligible
RCTs (Figure 2; k=1) [28,29]. With 6 studies from the previous
review [30–35], there were 8 treatment trials (Table 2).
There were 6 antidepressant studies [28–30,32,34,35] including
3 with post-MI patients that tested mirtazapine (in a RCT nested
within the MIND-IT study) [32], sertraline [34], and fluoxetine
[35]; 2 with HF patients that tested citalopram [28] and sertraline
[29]; and 1 with stable CHD patients that tested citalopram [30].
The 4 studies in post-MI and stable CHD patients all reported
positive, albeit small, effects (Hedges’s g=0.20–0.38). The 2
studies [28,29] that treated patients with HF, on the other hand,
did not find that citalopram [28] or sertraline [29] reduced
symptoms of depression compared to placebo. One small study of
citalopram in HF [28], however, was prematurely halted after an
unplanned interim analysis of a small number of patients (total
N= 37), which showed substantive symptom reduction in both the
citalopram and placebo groups. In the other study, the
SADHART-CHF trial [29], which enrolled 469 patients, patients
in both the sertraline and placebo groups both received nurse-
facilitated depression management support in addition to sertra-
line or placebo.
There were 2 studies where psychotherapy was investigated.
The Enhancing Recovery in Coronary Heart Disease Patients
(ENRICHD) trial [31], found that cognitive behavior therapy
reduced depressive symptoms (Hedges’s g=0.20, 95% confidence
interval [CI], 0.07 to 0.33). This was compared to usual care.
Figure 2. PRISMA Flow Diagram of Study Selection Process for Key Question #2.
doi:10.1371/journal.pone.0052654.g002
Depression Screening in Cardiovascular Care
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Among depressed patients enrolled in the ENRICHD trial, 28%
of patients in the cognitive behavior therapy intervention arm and
21% in the usual care arm were prescribed an antidepressant in
the 12 months following trial enrolment. The other psychotherapy
trial, the Canadian Cardiac Randomized Evaluation of Antide-
pressant and Psychotherapy Efficacy trial [30], was a parallel-
group, 262 factorial trial that compared citalopram to placebo
and short-term interpersonal psychotherapy plus clinical manage-
ment to clinical management alone in patients with CHD. Patients
in clinical management alone had lower levels of depressive
symptoms than patients who received interpersonal therapy,
although this was not statistically significant. In the CREATE
trial, patients who received citalopram, with or without interper-
sonal psychotherapy, were compared to patients who did not
receive citalopram, also with or without interpersonal psychother-
apy. Similarly, patients who received interpersonal psychotherapy
plus clinical management, with or without citalopram, were
compared to patients who received only clinical management, with
or without citalopram. Clinical management involved 20- to 25-
minute visits that included information on depression and
antidepressants, reassurance, and encouragement to adhere with
medication.
Figure 3 provides a forest plot of the effect sizes for reductions in
depressive symptoms for the primary outcome variables in each
treatment study.
No studies reported improved cardiac outcomes, although only
ENRICHD [31] and the Myocardial Infarction and Depression–
Intervention Trial (MIND-IT) [33] were designed for this purpose,
and MIND-IT had very low power (Table 3). MIND-IT was
designed as an effectiveness study that compared active depression
treatment to usual care. In MIND-IT, among patients not lost to
follow-up, 77% of patients randomized to the active depression
treatment received depression treatment via enrollment in a nested
double-blind mirtazapine versus placebo trial (48%) [32], by
receiving open pharmacological treatment (9%), or by receiving
non-pharmacological treatment (20%). Patients in the mirtazapine
trial who did not respond to mirtazapine treatment or placebo
were offered open pharmacological treatment at the end of the 12-
week trial period. Thus, there were 18 patients (9%) who were
included in the active depression intervention group, but only
received placebo as part of the mirtazapine trial. In the usual care
group, among patients not lost to follow-up, 17% received
pharmacological or non-pharmacological depression treatment
outside of the trial.
Risk of bias ratings are shown in File S8 for each treatment
study. Three trials were rated low risk of bias for most categories
[29–31], although 2 of the 3 [30–31] had higher risk associated
with the inability to blind participants and study personnel in trials
that involved psychotherapy. MIND-IT [33] was rated low risk in
most categories, but only reported depression outcomes 18 months
post-MI (0–9 months post-treatment), which may have reduced
observed effects of treatment. For the other 4 studies
[28,32,34,35], risk of bias was unclear or high across several
categories.
Figure 3. Forest Plot of Effect Sizes of Depression Treatment Studies (Key Question #2).
doi:10.1371/journal.pone.0052654.g003
Depression Screening in Cardiovascular Care
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Table 3. Outcomes for Randomized Controlled Trials of Depression Treatment.







Hedges’s g (95% CI)
Secondary Outcome(s):





DHAMD-24: 0.33 (0.10 to 0.56) DBDI-II: 0.34 (0.10 to 0.57)
DHAMD-17: 0.29 (0.05 to 0.52)
Cardiovascular serious
adverse events:{ Tx = 6
(4%); Placebo = 6 (4%);
OR = 1.00 (0.32 to 3.18)
IPT+ CM=142; CM
only = 142
DHAMD-24: 20.23 (20.46 to 0.00) DBDI-II: 0.10 (20.13 to 0.34)
DHAMD-17: 20.22 (20.46 to 0.01)
Cardiovascular serious
adverse events:{ Tx = 9
(6%); CM only = 3 (2%);
OR = 3.14 (0.83 to 11.83
ENRICHD, 2003,{
United States [31]
CBT = 474; UC= 481 DHAMD-17:1 0.20 (0.07 to 0.33) DBDI:1 0.31 (0.19 to 0.44) Recurrent MI or death
from any cause: Tx = 128
(27%); UC = 121 (25%);





DHAMD-17: 0.09 (20.56 to 0.73) DHAMD-31: 0.31 (20.34 to 0.95)






DHAMD-17: 0.35 (20.06 to 0.77) DBDI: 0.50 (0.08 to 0.91)
DSCL-90-D: 0.53 (0.11 to 0.95)
DCGI-S: 0.83 (0.40 to 1.26)
CGI-I: 0.30 (20.11 to 0.72)
Hospitalization: Tx = 8
(17%); Placebo = 10




Active Treatment = 209;
UC= 122
BDI:* 0.12 (20.15 to 0.39) NA Total cardiac events:"
Tx = 27 (14%); UC = 15







CGI-I: 0.20 (0.00 to 0.41) DHAMD-17:# 0.14
(20.06 to 0.35)
(1) Major adverse cardiac
events:**; Tx = 32 (17%);
Placebo= 41 (22%);
OR = 0.72 (0.43 to 1.21)
(2) All-cause mortality






DHAMD-17: 0.04 (20.14 to 0.22) NA All-cause mortality or
non-fatal cardiovascular
event: Tx = 65 (28%);
Control = 70 (30%);





DHAMD-17: 0.38 (20.16 to 0.92) NA Cardiac hospitalization:
Tx = 1 (4%); Placebo = 6
(22%); OR = 0.13 (0.02 to
1.21)
*All reported depression outcomes were assessed at the end of the treatment period except MIND-IT [33] where depression outcomes were assessed 18 months post-
myocardial infarction (0–9 months after completion of treatment).
{Cardiovascular serious adverse events =myocardial infarction, congestive heart failure, worsening angina, stroke, or other cardiovascular events.
{Of the 2,481 randomized patients in the ENRICHD trial who met eligibility criteria for MDD, minor depression, or dysthymia and/or low social support [31], data are
reported only for the subset of 955 randomized patients diagnosed with MDD. Original data for the ENRICHD trial were obtained from the National Heart Lung and
Blood Institute.
1In the depression outcome analyses presented, the last-observation-carried-forward approach was applied for missing data. The original published report of the
ENRICHD trial [31] reported outcome data for completers. Based on completer data only, D HAMD-17: Hedges’ g= 0.24, 95% CI 0.09 to 0.39 (N = 690, CBT: 348, UC: 342).
D BDI: Hedges’ g=0.36, 95% CI 0.21 to 0.51 (N = 699, CBT: 357, UC: 342).
IThe Honig, 2007 [32] study was an RCT nested within the MIND-IT study [33].
"Total cardiac events include cardiac death, recurrent myocardial infarction, revascularization, heart failure, myocardial ischemia, and ventricular arrhythmia. 17 patients
were lost to follow-up (Tx, n = 196; UC, n = 118).
#Patients were assessed with HAMD-17 at 16 weeks, but not 24 weeks.
**Major adverse cardiac events = events involving death or requiring hospitalization.
{{Hazard ratio from Kaplan-Meier analysis, but number of deaths per group not provided for follow-up study (Glassman AH, Bigger JT,Jr, Gaffney M. Psychiatric
characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: Seven-year follow-up of SADHART
participants. Arch Gen Psychiatry. 2009 Sep;66:1022–9). BDI = Beck Depression Inventory; BDI-II = Beck Depression Inventory – II; CBT = cognitive behavior therapy;
CM= clinical management; CGI-I = Clinical Global Impression-Improvement; CGI-S =Clinical Global Impression-Severity; CI = confidence interval; CREATE =Canadian
Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy trial; ENRICHD= Enhancing Recovery in Coronary Heart Disease Patients; HAMD-17 = 17-
item Hamilton Depression Rating Scale; HAMD-24 = 24-item Hamilton Depression Rating Scale; HAMD-31 = 31-item Hamilton Depression Rating Scale;
IPT = interpersonal therapy; MADRS =Montgomery-Asberg Depression Rating Scale; MI =myocardial infarction; MIND-IT =Myocardial Infarction and Depression-
Intervention trial; NA= not applicable; SADHART = Sertraline Antidepressant Heart Attack Randomized trial; SADHART-CHF = Sertraline Against Depression and Heart
Disease in Chronic Heart Failure; SCL-90-D = depression subscale of the Symptom Checklist 90; Tx = treatment; UC = usual care.
doi:10.1371/journal.pone.0052654.t003
Depression Screening in Cardiovascular Care
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Key Question #3: Depression Screening
Of 1,453 unique titles/abstracts, 1 received full-text review, and
no eligible RCTs were identified (Figure 4). Potentially relevant
excluded studies are described in File S9.
Discussion
The main findings of this systematic review are that: (1) there
are few examples of screening tools with high sensitivity and
specificity using an a priori-defined cutoff score in more than one
CHD sample. When results from studies that used a pre-specified
score were available in more than one sample, estimates of
diagnostic accuracy were inconsistent. When exploratory data
analysis methods were used to both generate a cutoff score and
assess the accuracy of that cutoff score in the same sample,
different studies tended to produce cutoffs that were inconsistent
across studies; (2) depression treatment improves symptoms of
depression in post-MI and stable CHD patients, although
symptom reductions are modest; (3) antidepressant treatment has
not reduced depressive symptoms compared to placebo in two
trials with HF patients, although one small trial was stopped
prematurely, and the other trial provided nurse-facilitated
depression management services to patients in both the antide-
pressant and placebo groups; and (4) no RCTs have evaluated
whether routine depression screening in CHD would improve
depression outcomes.
The AHA has recommended that all CHD patients be routinely
screened for depression [3], but the present systematic review did
not find any evidence that depression screening would improve
outcomes. This finding is not unique to CHD, since there are no
published trials in any patient group where patients screened for
depression had better depression outcomes than patients not
screened [36]. On the other hand, a 2008 meta-analysis [37]
reviewed 11 trials of depression screening in primary care and
found several trials where screening increased identification or
treatment of depression, but none where screening improved
depression outcomes, even though primary care settings are
generally much better equipped to manage mental health
problems than cardiology settings.
In cardiovascular care settings, several observational studies
have reported on the administration of depression questionnaires.
One study [38] examined the 2-step protocol recommended by the
AHA [3], in which the 2-item PHQ-2 was administered to 3,504
of 4,873 admitted patients, and patients with a positive PHQ-2
screen were administered the PHQ-9. Using this approach, 140
patients were identified as possibly depressed. The study authors
concluded that depression screening is feasible, but did not
describe the referral and follow-up process, estimate costs, or assess
Figure 4. PRISMA Flow Diagram of Study Selection Process for Key Question #3.
doi:10.1371/journal.pone.0052654.g004
Depression Screening in Cardiovascular Care
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whether benefit was obtained. Other observational studies have
reported that implementing screening did not increase recognition
of depression compared to settings without screening [39]; that no
new, previously unrecognized cases of depression were identified
through screening [40]; and that patients with positive depression
screens only received follow-up assessments if there was a
psychiatrist physically present in the cardiology clinic at the time
of the screening, but not if an outpatient psychiatry referral was
made [41].
In primary care, the UK’s Quality and Outcomes Framework
pay-for-performance program introduced routine depression
screening for patients with CHD or diabetes in April 2006 [42].
In this context, a retrospective cohort study [42] examined records
from April 2007 through March 2008 of 94,570 CHD or diabetes
patients from 237 general practices in Scotland, including 1,245
physicians. Of all patients with CHD or diabetes, 67,358 were
screened for depression (71%), and 2,269 of those screened (3%)
received a new diagnosis of depression or initiated treatment. The
number needed to screen was 976 for a new diagnosis of
depression and 687 for initiation of antidepressant treatment. Data
were not available to determine screening resulted in improved
depression outcomes.
The AHA website lists more than 20 patient care guidelines
issued since the 2008 AHA Advisory on depression screening [3].
None has recommended that routine screening be implemented as
recommended in the Advisory. One guideline statement on
secondary prevention [43] cited a 2009 editorial that urged the
AHA to reconsider its depression screening recommendation [44]
and suggested that depression screening in CHD might be
considered, but only if patients have access to case management
services in collaboration with their primary care physician and a
mental health specialist. This recommendation differs from the
AHA Science Advisory, which recommended routine screening
followed by referral of all positive screening results for evaluation
by a professional qualified in the diagnosis and management of
depression. It is closer to the U.S. Preventive Services Task Force
depression screening recommendation for primary care [45],
which specifies that screening should only occur when integrated
depression care systems for evaluation and case management are
available. No trials, however, have assessed whether screening in
CHD with referral to primary care would benefit patients, and no
trials have shown that screening in the context of integrated
depression care systems would benefit patients even in primary
care [36]. This was an important reason why the UK National
Institute of Clinical Excellence [46] did not recommend routine
depression screening in primary care. Consistent with this, the
authors of the Scottish primary care study [42] concluded that the
impact of depression screening, even in terms of case identification
and new treatment, were small and that health care systems should
carefully consider the resource implications of these programs.
Depression screening can benefit patients only to the extent that
it identifies depressed patients not already diagnosed or treated for
depression, successfully enrolls those patients in treatment, and
achieves positive treatment results. As described recently [36],
antidepressant treatment rates are already high and trending
upward in CHD patients [47]. By 2002, for instance, 16% of post-
MI patients aged 65 and older in Ontario, Canada were
prescribed antidepressant medication [48]. Furthermore, existing
studies appear to exaggerate the accuracy of depression screening
tools due to the inclusion of already diagnosed and treated
patients, who would not be screened in clinical practice [49], as
well as due to the selective reporting of well-performing results
from cutoff scores that generate high levels of accuracy, even
though this results in substantially different cutoffs being reported
across studies [50]. Finally, treatment of depression is more
effective in patients with high levels of symptoms, and most of
those who are newly detected via screening would be expected to
have less severe symptoms of depression [36].
Without evidence that depression screening benefits CHD
patients, the potentially considerable resources and costs that
would be involved in implementing routine screening must be
even more carefully considered [51]. Practically speaking, costs
would include not only administering screening tests to all CHD
patients, but also following up on positive depression screens that
would be expected in perhaps one-third of all CHD patients [5],
even though most would turn out not to be depressed. The optimal
interval and associated costs of rescreening must also be
considered as ongoing screening would be expected to divert
scarce resources away from an overburdened mental health system
that already struggles to provide adequate mental health care [36].
Depression screening would almost certainly increase the
number of patients using antidepressants, and potential harms of
even more widespread use of antidepressants by CHD patients
must therefore be considered. Selective serotonin reuptake
inhibitors (SSRIs) may act as antiplatelet agents, which can
increase the risk of major bleeding, especially when used along
with the combination of aspirin and a thienopyridine antiplatelet
drug like clopidogrel [52] or in patients taking warfarin [53,54]. In
addition to this risk, many antidepressant drugs inhibit cytochrome
P450 isoenzymes and can result in important drug-drug interac-
tions with cardiac medications [55]. For example, an interaction in
patients with acute MI between the SSRI paroxetine and the
commonly-prescribed beta blocker metoprolol has been described
[56]. In addition to the well-recognized cardiac risks of the tricyclic
antidepressants [57], the serotonin-norepinephrine reuptake
inhibitor antidepressants may increase blood pressure and heart
rate [58], and several antidepressant classes may have unfavorable
effects on heart rate variability [59]. Reports of potential adverse
cardiovascular effects of antidepressant drugs [60–64] suggest that
additional studies that evaluate cardiovascular side effects of
antidepressant drugs in greater numbers of patients followed for
longer time periods may be warranted.
The AHA recommendation for depression screening in CHD
[3] was made without any evidence that this would improve
depression outcomes. The present systematic review shows that,
nearly 4 years since the AHA recommendation on depression
screening, there is still no evidence that demonstrates that this
potentially very costly strategy would benefit patients. There are
prior examples where the AHA has recognized the lack of
evidence supporting recommendations and, commendably, re-
vised those recommendations [7]. We hope that the AHA will
similarly reconsider its recommendation for depression screening
of all CHD patients.
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